Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Direxion Daily S&P 500 Bear 3X Shares ETF
SPXS
5
ProShares UltraPro Short S&P500 ETF
SPXU
US Stock MarketDetailed Quotes
BEAM Beam Therapeutics
- 19.450
- -0.260-1.32%
Trading Apr 30 12:52 ET
1.96BMarket Cap-4.25P/E (TTM)
19.520High18.912Low1.00MVolume19.130Open19.710Pre Close19.20MTurnover1.10%Turnover RatioLossP/E (Static)100.56MShares35.25052wk High2.67P/B1.77BFloat Cap13.52552wk Low--Dividend TTM91.03MShs Float138.522Historical High--Div YieldTTM3.08%Amplitude13.000Historical Low19.192Avg Price1Lot Size
About Beam Therapeutics Company
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Company Profile
SymbolBEAM
Company NameBeam Therapeutics
Listing DateFeb 6, 2020
Issue Price17.00
Founded2017
CEOMr. John Evans
MarketNASDAQ
Employees483
Fiscal Year Ends12-31
Address238 Main Street,9th floor
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142-1016
Phone1-857-327-8775
Websitehttp://www.beamtx.com
Company Executives
- Name
- Position
- Salary
- Sravan K. Emany
- Chief Financial Officer
- 4.82M
- Dr. Christine Bellon, PhD
- Chief Legal Officer and Secretary
- 2.58M
- Dr. Amy Simon, M.D.
- Chief Medical Officer
- 2.62M
- Bethany J. Cavanagh
- Principal Accounting Officer, Treasurer and Senior Vice President, Finance
- --
- Dr. Giuseppe Ciaramella, PhD
- President
- 3.38M
- John Evans
- Chief Executive Office and Director
- 6.41M
- Chirfi Guindo
- Director
- 774.60K
- Kathleen E. Walsh
- Independent Director
- 447.74K
- Christi Shaw
- Independent Director
- 444.39K
- Graham K. Cooper
- Independent Director
- 450.24K
- Dr. Mark C. Fishman, M.D.
- Lead Independent Director
- 485.20K
- Dr. John M. Maraganore,PhD
- Independent Director
- 447.04K
- Dr. Carole Ho, M.D.
- Independent Director
- 449.10K
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
